Abdul-Mutakabbir JC, Griffith NC, Shields RK, Tverdek FP, Escobar ZK (2021) Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases Pharmacists. Infect Dis Ther 10(4):2177–2202

Article  PubMed  PubMed Central  Google Scholar 

World Health Organisation (2017) WHO publishes list of bacteria for which new antibiotics are urgently needed, accessed on Dec 12, 2021. https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

Isler B, Doi Y, Bonomo RA, Paterson DL (2018) New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 63(1):e01110–e01118

PubMed  PubMed Central  Google Scholar 

Da Silva GJ, Domingues S (2017) Interplay between colistin resistance, virulence and fitness in Acinetobacter baumannii. Antibiotics (Basel) 6(4):28

Article  PubMed  Google Scholar 

Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240

Article  CAS  PubMed  Google Scholar 

Fluit AC, Florijn A, Verhoef J, Milatovic D (2005) Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 49(4):1636–1638

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seifert H, Stefanik D, Sutcliffe JA, Higgins PG (2018) In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 51(1):62–64

Article  CAS  PubMed  Google Scholar 

Gong J, Su D, Shang J, Yu H, Du G, Lin Y et al (2019) Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis. Medicine (Baltimore) 98(38):e17091

Article  CAS  PubMed  Google Scholar 

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2022) Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 75(2):187–212

Article  PubMed  PubMed Central  Google Scholar 

Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J et al (2015) Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother 59(3):1680–1689

Article  PubMed  PubMed Central  Google Scholar 

Vijayakumar S, Gopi R, Gunasekaran P, Bharathy M, Walia K, Anandan S, Veeraraghavan B (2016) Molecular characterization of invasive carbapenem-resistant Acinetobacter baumannii from a tertiary care hospital in South India. Infect Dis Ther 5(3):379–387

Article  PubMed  PubMed Central  Google Scholar 

Clinical and Laboratory Standards Institute (2012) Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA

Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM et al (2010) Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54(11):4678–4683

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS et al (2017) High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model. Antimicrob Agents Chemother 61(3):e01268-e1316

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Shu Y, Zhu F, Feng B, Zhang Z, Liu L et al (2021) Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist 24:136–147

Article  CAS  PubMed  Google Scholar 

Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J (2013) Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 17(4):389–394

Article  PubMed  PubMed Central  Google Scholar 

Karlowsky JA, Hackel MA, McLeod SM, Miller AA (2022) In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother 66(9):e0078122

Article  PubMed  Google Scholar 

Petropoulou D, Siopi M, Vourli S, Pournaras S (2022) Activity of sulbactam-durlobactam and comparators against a national collection of carbapenem-resistant Acinetobacter baumannii isolates from Greece. Front Cell Infect Microbiol 11:814530

Article  PubMed  PubMed Central  Google Scholar 

Pasteran F, Cedano J, Baez M, Albornoz E, Rapoport M, Osteria J et al (2021) A new twist: the combination of sulbactam/avibactam enhances sulbactam activity against carbapenem-resistant Acinetobacter baumannii (CRAB) Isolates. Antibiotics (Basel) 10(5):577

Article  CAS  PubMed  Google Scholar 

Ni W, Han Y, Zhao J, Wei C, Cui J, Wang R et al (2016) Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents 47(2):107–116

Article  CAS  PubMed  Google Scholar 

Yin T, Lai JJ, Huang WC, Kuo SC, Chiang TT, Yang YS et al (2022) In vitro and in vivo comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant Acinetobacter baumannii. J Chemother 34(3):166–172

Article  CAS  PubMed  Google Scholar 

Deng Y, Chen L, Yue M, Huang X, Yang Y, Yu H (2022) Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. BMC Infect Dis 22(1):795

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fragkou PC, Poulakou G, Blizou A, Blizou M, Rapti V, Karageorgopoulos DE (2019) The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence. Microorganisms 7(6):159

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beganovic M, Daffinee KE, Luther MK, LaPlante KL (2021) Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 65(3):e01680-e1720

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F et al (2016) Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76(5):567–588

Article  CAS  PubMed  Google Scholar 

Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S (2022) Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 66(5):e0214221

Article  PubMed  Google Scholar